Monitoring agency report: nil deviation from IPO objects, after objects and timelines were revised
Senores Pharmaceuticals has shared CARE Ratings' monitoring agency report on the use of its IPO proceeds for the quarter ended September 30, 2026.
By ScoutQuest · · 2 min read
- Deviation from objects of the issue
- Nil
- IPO size
- Rs.500.00 crore fresh issue
- Report period
- quarter ended September 30, 2026
Senores Pharmaceuticals has submitted CARE Ratings' monitoring agency report on the use of its IPO proceeds for the quarter ended September 30, 2026. Such a report is a periodic outside check on whether money raised in an IPO is going where the company said it would.
What the report records
- Deviation from the objects of the issue: Nil
- Whether all utilisation is as per the disclosures in the Offer Document: No
- Shareholder approval obtained in case of material deviation: Yes
- Major deviation observed over earlier monitoring agency reports: Yes
- Whether the means of finance for the disclosed objects have changed: No
- Government/statutory approvals related to the objects: Yes, as applicable
- Favourable or unfavourable events affecting the viability of the objects: No
- Any other information that may materially affect investor decisions: No
Why two answers read the way they do
The "No" on utilisation matching the Offer Document, and the "Yes" on a major deviation from earlier reports, both trace to one event. The company sought shareholder approval for a variation in the objects or terms of utilisation of the IPO proceeds and for an extension of the time limit, through a postal ballot. Members approved it by e-voting, as recorded in the scrutinizer report dated August 04, 2026. The objects and their timelines were then revised accordingly.
Put plainly: measured against the revised objects, the monitoring agency found no deviation this quarter. The change in how the IPO money is to be used was put to a shareholder vote and passed.
What the checks rest on
The figures are supported by a chartered accountant certificate from M/s. Pankaj R. Shah & Associates dated October 23, 2026, along with bank statements, a company declaration and the shareholder approval. The report was reviewed by the Audit Committee and taken on record by the Board of Directors on October 29, 2026.
Numbers to note
- IPO size: Rs.500.00 crore of fresh issue; the issue period ran from December 20, 2024 to December 24, 2024.
- The report's own definition of a material deviation includes funds actually utilised differing by more than 10% from the amount projected in the offer documents.
What stands out for a retail investor
Against the current objects there is nil deviation, the means of finance is unchanged, statutory approvals are in place as applicable, and no event is flagged as affecting the viability of the objects. The revision of the objects and timelines is the item to be aware of, and it carries member approval through the postal ballot.
Also from Senores Pharmaceuticals
Subsidiary's Mehsana facility awarded PIC/S GMP certification by Ukraine's SMDC
17 Nov 2026
Q2 & H1FY27 call transcript: management reaffirms FY27 growth guidance
5 Nov 2026
Senores Pharmaceuticals files audio recording of Q2 & H1FY27 earnings conference call held October 29, 2026
29 Oct 2026
More numbers
- IPO issue size (fresh issue)Rs.500.00 crore
- Deviation from the objects of the issueNil
- Threshold used to define material deviation in funds utilised10%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.